Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age

Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age The Pfizer-BioNTech and Moderna COVID-19 vaccines are mRNA vaccines that were initially authorized by Health Canada for use in individuals 16 and 18 years of age and older, respectively, in December 2020. On May 5, 2021, Health Canada expanded the Interim Order authorization for the Pfizer-BioNTech COVID-19 vaccine to also include adolescents 12 to 15 years of age based on clinical trial results in this age group. 2021-11-05 Public Health Agency of Canada open-ouvert@tbs-sct.gc.ca Health and SafetyCOVID-19COVIDvaccinationPfizer-BioNTechModernavaccinesimmunizationpublichealthmeasuresPHMsguidancedocumenthealthcaresystempublic healthhealthauthoritiespandemiccoronavirusRecommendationusemRNAvaccinesadolescents12 to 17years of age Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of ageHTML https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/mrna-adolescents.html Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of ageHTML https://www.canada.ca/fr/sante-publique/services/immunisation/comite-consultatif-national-immunisation-ccni/recommandations-utilisation-vaccins-covid-19/arnm-adolescents.html

The Pfizer-BioNTech and Moderna COVID-19 vaccines are mRNA vaccines that were initially authorized by Health Canada for use in individuals 16 and 18 years of age and older, respectively, in December 2020. On May 5, 2021, Health Canada expanded the Interim Order authorization for the Pfizer-BioNTech COVID-19 vaccine to also include adolescents 12 to 15 years of age based on clinical trial results in this age group.

Data and Resources

Similar records